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63.1  Introduction
Breast cancer (BC) is often mistakenly thought of as a 
female-only disease. Aside from the expected cultural expla-
nations, the simple fact is that male BC (MBC) is rare. To 
date, in Western countries, MBC accounts for less than 1% 
of all cancers in men and less than 1% of all BCs, but its 
incidence is increasing [1, 2].
The earliest reference to BC in the Edwin Smith Surgical 
Papyrus from Egypt (3000–2500 BC) appears to have 
referred to a man [3, 4]. The first clinical description of an 
MBC case is in the early fourteenth century and is attributed 
to John of Arderne (1307–1390) who recorded the several- 
year evolution of nipple ulceration in a priest, with the sub-
sequent development of BC [5]. Many years later, in 1842, 
Domenico Antonio Rigoni-Stern showed to the Congress of 
the Italian Scientist that the risk of BC was greatly increased 
in nuns compared to other women, and, intriguingly, he con-
cluded his presentation saying that “the four men found to 
have died of BC were all priests” [6].
Because of its rarity, MBC is often compared with FBC, 
and our current understanding regarding MBC biology, 
pathology, and treatment strategies has been largely extrapo-
lated from the more common female counterpart. Current 
epidemiologic and pathologic data, such as age-frequency 
distribution, age-specific incidence rate patterns, and prog-
nostic factor profiles, suggest that MBC is like postmeno-
pausal FBC [7]. Although MBC resembles postmenopausal 
FBC, clinical and pathologic characteristics of MBC do not 
exactly overlap FBC. Compared with FBC, MBC occurs 
later in life with more advanced stage, lower histologic 
grade, and more frequent estrogen receptor (ER)- and pro-
gesterone receptor (PR)-positive (ER/PR+) status [8, 9]. 
Higher stage and advanced age at diagnosis are negative 
prognostic factors, and, although rare, MBC remains a sub-
stantial cause for morbidity and mortality in men.
There is very little research on the management and care 
of MBC, and, due to the low incidence of MBC, studies are 
often small and underpowered. Thus, to date, therapy has 
been based largely on biomarkers developed for FBC, and 
MBC treatment generally follows the same indications as 
postmenopausal FBC. The outcome for men is the same as 
women stage for stage, but overall the prognosis tends to be 
worse in MBC [7]. This is usually due to a delay in presenta-
tion, leading to a large proportion of patients presenting with 
advanced-stage disease, and older age at diagnosis, leading 
to the coexistence of possible comorbidities. Overall, BC 
mortality and survival rates have improved significantly over 
time for both male and female BC, but the improvement for 
male is smaller if compared to female patients [9]. The dif-
ferent treatment outcomes may suggest a non-appropriate 
utilization of treatment options and a possible existence of 
different underlying pathogenetic mechanisms between male 
and female BC.
Today, thanks to the increasing number of collaborative 
studies and to the combination of data derived from new 
high-throughput technologies, we are now able to hypothe-
size that despite the similarities between female and male 
BC, MBC could be rather considered a distinct pathology.
63.2  Epidemiology
MBC incidence varies greatly in different geographical areas 
and ethnic groups and is correlated with FBC incidence 
worldwide [10]. Indeed, the worldwide variation of MBC 
resembles that of FBC, with higher rates in North America 
and Europe and lower rates in Asia [11]. A substantial high 
proportion of MBC cases have been reported in Africa, par-
ticularly in Uganda and Zambia [12]. These relatively high 
rates have been attributed to endemic infectious diseases 
causing liver damage leading to hyperestrogenisms. Overall, 
black men have a higher incidence of MBC (1.8 per 100,000) 
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compared to the average incidence. By contrast, the annual 
incidence of MBC in Japan is significantly lower (5 per 
1000,000) than the average incidence (1 per 100,000), com-
parable to the lower than the average incidence of FBC in 
this country [8, 13].
MBC incidence is increasing [2]. Data from the National 
Cancer Institute Surveillance, Epidemiology, and End 
Results (SEER) database indicates that in the USA the inci-
dence of MBC has been increasing during the last 20 years, 
from about 1 per 100,000 to around 1.2 per 100,000 (SEER 
13 Registries Database). Data from the United Kingdom 
Association of Cancer Registries (UKACR) have reported 
that in the UK, MBC incidence is on the increase and paral-
lels US data over a similar period of time [14].
Age-specific incidence rates for MBC increase linearly 
and steadily with age with a peak incidence in the late 60s. In 
contrast, FBC increases rapidly until around age 50 and then 
increases at a slower rate for older women (Fig. 63.1). MBC 
cases are diagnosed at a more advanced age than FBC. Age of 
BC presentation in males is mostly in the late 60s, which is 
about 10 years greater than in female. In the SEER database, 
the median ages at diagnosis of BC were 68 and 61 years in 
males and females, respectively. The differences in incidence 
rates and time trends between males and females may reflect 
gender-related differences in risk factors and/or different 
underlying pathogenetic mechanisms. On the other hand, the 
correlation between male and female BC  incidences indicates 
the existence of common risk factors for BC in both genders.
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Fig. 63.1 Age-specific 
incidence rates (per 100,000) 
for male and female invasive 
breast cancer in white US 
population. Data source: 
SEER 18, years 2003–2012
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63.3  Risk Factors
Risk factors for MBC include genetic, hormonal, and envi-
ronmental factors (Table 63.1).
63.3.1  Genetics
About 20% of male patients with BC have positive family 
history for BC. Men with a positive first-degree family his-
tory have a twofold increased risk of BC. The risk increases 
with increasing numbers of first-degree relatives affected, 
and a particularly enhanced risk (more than ninefold) is 
reported for cases with both an affected mother and an 
affected sister [15]. About 2% of male patients with BC 
develop a second primary BC, and more than 20% develop a 
second non-breast tumor, more frequently prostate, colon, 
and genitourinary cancer. Men who have family members 
with Cowden syndrome and Lynch syndrome are also at 
increased risk for BC [16, 17]. As both these syndromes and 
MBC are rare, it is difficult to determine as to whether germ- 
line mutations in these genes increase the risk of MBC.
Mutations in the two major high-penetrance BC genes, 
BRCA1 and, predominantly, BRCA2, account for approxi-
mately 10% of MBCs, outside populations with BRCA 
founder mutations [18]. In Icelandic population, for exam-
ple, the BRCA2 999del5 founder mutation is implicated in 
about 40% of MBC cases [19]. Mutations in BRCA1 and 
BRCA2 genes are often found in MBC patients who have 
multiple cases of breast and/or ovarian cancer in their family, 
but have also been found in MBC patients with no breast 
and/or ovarian cancer family history. This evidence and the 
rarity of the disease indicate that every man who has BC 
should be routinely screened for BRCA1 and BRCA2 muta-
tions, regardless of family history, which could prove to con-
tribute invaluable genetic information to family members. 
Men with BRCA1/2 mutations have an increased risk of BC 
compared with general population and develop BC at 
younger age compared with non-mutation carriers. The life-
time risk of developing MBC has been estimated to be in the 
range of 1–5% for BRCA1 and 5–10% for BRCA2 mutation 
carriers, compared with a risk of 0.1% in the general popula-
tion [20, 21]. The median age at BC diagnosis in male 
BRCA1 and BRCA2 mutation carriers is earlier (62 years) 
than that of the general population (68 years) (SEER 13 
Registries Database).
Two genes, CHEK2 and Partner/Localizer of BRCA2 
(PALB2), both functionally related to BRCA1 and BRCA2 in 
DNA repair pathways, also play a role in MBC susceptibility 
as moderate-penetrance genes. In certain populations, the 
CHEK2 1100delC mutation confers an increased risk of 
MBC, particularly in BRCA1 and BRCA2 mutation-negative 
BC families. However, this association is not so evident in 
MBC cases unselected for family history, and the contribu-
tion of the CHEK2 1100delC variant to MBC predisposition 
varies from one ethnic group and from one country to another 
[22–24]. Mutations in PALB2 have been reported in families 
with female and male BC cases [25–27]. A fourfold higher 
frequency of MBC among relatives of PALB2 mutation car-
riers has been shown. BC risk estimates for male PALB2 
mutation carriers still remain to be precisely assessed; how-
ever, PALB2 may have an important role in MBC predisposi-
tion, at a comparable extent as for FBC [28].
A number of single nucleotide polymorphisms (SNPs) 
are implicated as low-penetrance alleles in MBC genetic 
predisposition [29]. The majority of SNPs that are associ-
ated with MBC risk are the same as those associated with 
FBC risk, but it appears that the magnitude of risk con-
ferred by them differs between the two diseases. In partic-
ular, two SNPs (rs3803662 and rs1314913) have been 
identified significantly associated with MBC risk [30]. The 
rs3803662 localizes to the TOX High Mobility Group Box 
Family Member 3 (TOX3) gene (mapping to 16q12.1) and 
is a known modifier of FBC risk [31]. As shown for rare 
variants in BRCA2 and CHEK2 genes, the association with 
risk for this SNP is greater in males compared with females 
[30]. The rs1314913 SNP, located in intron 7 of the 
RAD51B gene (mapping to 14q23-24.2) belonging to 
RAD51 DNA repair family, is specifically associated with 
increased MBC but not FBC risk, supporting defined dif-
ference between male and female disease [32]. While the 
risk associated with these SNPs is low, they are likely to be 
Table 63.1 Risk factors for male breast cancer
Risk Factors Genetic Hormonal Environmental
Well established Breast cancer family history Increased estrogen exposure Radiation
BRCA1/BRCA2 Deficiency of testosterone
Klinefelter’s syndrome Testicular disease
Possible CHEK2 Obesity Heat
PALB2 Diabetes Electromagnetic fields
SNPs Liver damage Polycyclic aromatic hydrocarbons
Suspected Cowden syndrome Gynecomastia Alcohol
Lynch syndrome Tobacco
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responsible for a substantial percentage of hereditary and 
sporadic MBCs because of their high frequency in the 
population.
63.3.2  Endocrine
MBC is recognized as being a hormone-dependent malig-
nancy, and it is widely accepted as an estrogen-driven dis-
ease, specifically related to hyperestrogenism [33]. Clinical 
disorders associated with imbalanced estrogen/androgen 
ratio that result in abnormal estrogen exposure represent a 
major risk. Men affected with Klinefelter’s syndrome, a 
rare congenital condition characterized by a 47 XXY karyo-
type and high levels of estrogens and low levels of testos-
terone, have been shown to have 20- to 50-fold increased 
MBC risk [34].
Other medical conditions linked to altered endogenous 
hormones including diabetes, orchitis, cryptorchidism, and 
gynecomastia have possible influences on MBC risk [35]. 
In addition, liver disease, leading to hyperestrogenism, 
emerged as a significant risk predictor of MBC, particularly 
among black men [36]. Conditions increasing exposure to 
estrogen or decreasing exposure to androgen, such as the 
long-term use of antiandrogens and estrogens in the treat-
ment of prostate cancer, the exogenous administration of 
estrogen to transsexuals, or abuse of steroids for physical 
performances, have also been implicated as causative fac-
tors for MBC [37–39]. Elevated risks of MBC have also 
been related to a variety of other conditions associated with 
altered endogenous hormones, with the most consistent 
association being observed with obesity [40, 41]. Obesity is 
associated with an increased risk of postmenopausal FBC, 
presumably through peripheral conversion of androgens to 
estrogens. In men, obesity is associated with decreased tes-
tosterone and sex hormone-binding globulin levels but 
increased estrogen levels [42, 43], thus leading to greater 
estrogen bioavailability.
63.3.3  Environmental and Lifestyle Risk 
Factors
Ionizing radiations, occupational exposure to heat, and 
electromagnetic radiation have been considered as possi-
ble causal cofactors in the etiology of MBC [12]. 
Additional clues to a potential importance of other occu-
pational exposures derive from studies showing elevated 
MBC risks among men exposed to polycyclic aromatic 
hydrocarbons [18, 44]. Some lifestyle factors have also 
been involved in the etiology, including alcohol and 
tobacco exposures, although results have varied across 
investigations [45].
63.4  Histopathology
63.4.1  Histology
The histology of BC occurring in men is generally similar to 
that occurring among women although the distribution of the 
histological types is different. The majority of MBCs are 
invasive ductal carcinoma (more than 80%) followed by duc-
tal carcinoma in situ (about 10%). Lobular histotype is much 
less common in men (1.5%) than in women, due to the 
absence of terminal lobules in male breast tissue [46, 47]. 
Lobular histotype has been reported in association with 
Klinefelter’s syndrome and, rarely, in men with no previous 
history of estrogen exposure. The rare tumor types, such as 
medullary, tubular, mucinous, and squamous carcinomas, are 
also reported in men although they are rarer than in women. 
On the other hand, papillary carcinoma is more frequent in 
men than in women. Both Paget’s disease and inflammatory 
carcinoma are observed with equal frequency (about 1%) in 
both genders [12]. The majority of MBCs are low histologic 
grade [46, 47]. Data from the SEER 13 database show that 
13% of MBCs are Grade 1 (G1), 50% Grade 2 (G2), and 
39% Grade 3 (G3) tumors (Table 63.2) [43].
63.4.2  Biomarkers
The great majority of MBCs are ER+ and PR+ with more than 
90% of tumors being positive for ER and about 85% for PR 
(SEER13, [43]). As reported for FBC, the percentage of men 
with ER+ BC significantly increases with patient age [1, 8]. 
Rates of androgen receptor (AR) expression in MBC have 
been variable in different cohorts, ranging from 39 to 95% 
[12, 48, 49]. Data about HER2 expression in MBC are incon-
sistent most likely because of small studies and of not stan-
dardized technical approaches. Studies performed by using 
both immunohistochemical (IHC) and fluorescence in situ 
Table 63.2 Histopathology of male breast cancer
Histology %
Invasive ductal carcinoma 85–95
Ductal carcinoma in situ 5–10
Invasive papillary 2–5
Lobular 1–1.5
Medullary 2
Mucinous 1
Paget’s 1
Biomarkers %
ER 90
PR 85
AR 39–95
HER2 15
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hybridization (FISH) analyses report HER2 overexpression 
in about 15% of MBCs [50, 51].
Based on immunophenotypic characteristics, MBC can 
be classified into different molecular subtypes [50, 52]. 
Luminal A (ER+ and/or PR+, HER2-) subtype has been 
reported as the most common subtype in MBC (more than 
85%), whereas Luminal B (ER+ and/or PR+, HER2+) sub-
type has been less frequently observed (about 12%). Triple- 
negative (ER-, PR-, HER2-) subtype and HER2-positive 
(ER-, PR-, HER2+) subtype have been rarely identified in 
MBC (about 1%).
63.4.3  BRCA1/2 Male Breast Cancer
Generally MBC presents with lower histologic grade 
tumors than FBC. In contrast, MBC associated with 
BRCA2 mutations presents with higher histologic grade 
compared both with FBC in BRCA2 mutation carriers and 
with MBC in the general population from SEER [53]. In 
particular, high histologic grade breast tumors are more 
frequent among male BRCA2 mutation carriers diagnosed 
at younger ages (below 50 years) than among those diag-
nosed at older ages. Thus, the identification of a specific 
BRCA2-associated phenotype suggestive of an aggressive 
behavior may define a subset of MBC patients (i.e., patients 
with high-grade breast tumors and with young age at diag-
nosis) who might particularly benefit from adjuvant che-
motherapy. A similar trend is also observed for BRCA1 
mutation carriers. Overall, BRCA1/2 MBCs display dis-
tinct pathologic characteristics compared to BRCA1/2 
FBCs. These findings should lead to the development of 
gender-specific risk-prediction models and guide clinical 
strategies appropriate for MBC management.
63.5  Clinical Presentation and Diagnosis
Men with BC are more frequently diagnosed at a more 
advanced age and with a more severe clinical presentation, 
with greater tumor size and a more frequent lymph node 
involvement, than women with BC. In general, this is thought 
to reflect diagnostic delay in a population unaware of its risk 
and not appropriately encouraged to undergo routine BC 
screening. Despite increasing awareness of MBC, there 
remains an average delay from the onset of symptoms to 
diagnosis of 6–10 months [54].
The most common symptom of BC in men is a painless 
lump. The majority of MBC patients present a palpable 
subareolar mass. Because of the unique anatomy of 
the male breast, characterized by the presence of the rudi-
mentary breast ducts located directly beneath the nipple, 
other initial symptoms may include nipple involvement 
such as retraction, ulceration, discharge, and bleeding 
[54]. BC primaries in men more often have locoregional 
metastasis at presentation. More than 40% of MBC 
patients present with stage III/IV disease, often due to 
early chest wall spread. Clinically suspected axillary 
nodes are identified in about 40% of patients at the time of 
diagnosis [46]. Bilateral involvement is rare, less than 2% 
of MBC cases [55].
Clinically suspicious lesions identified by palpation 
are evaluated with mammography and/or ultrasonography 
scans to select patients who will undergo to further exami-
nation generally made by fine-needle aspiration (FNA) or 
core biopsy. The primary differential diagnosis of a breast 
mass in a man includes gynecomastia that affects 30% of 
healthy men [56]. The evaluation of the extension of dis-
ease and stage classification follows the guidelines for 
FBC.
63.6  Prognosis and Survival
Prognosis depends upon tumor size, histologic grade, nodal 
status, and hormone receptor status. Stage classification of 
male patients with BC is similar to that of female patients, 
according to AJCC or UICC guidelines. As postmenopausal 
FBC, in general MBC have more favorable prognostic factor 
profile, including low histologic grade and hormonal 
receptor- positive expression [9]. Despite this, men experi-
ence worse prognosis than women, probably due to both an 
advanced stage and older age at diagnosis. As in FBC, the 
most important prognostic indicators are tumor size and 
lymph node status. Men with breast tumor diameter > 2 cm 
have a 40% higher risk of mortality than men with tumors 
<2 cm. Similarly, men with lymph node involvement have a 
50% higher risk of mortality than men without lymph node 
involvement. Furthermore, an increasing number of lymph 
node metastases are positively correlated with a poorer prog-
nosis [1].
Compared with women, overall survival rates are lower 
in men; however, when adjusted for older age at diagnosis 
and poor life expectancy, the relative survival rates are quite 
similar for men and women [9]. This likely reflects the 
influence of serious comorbidities as result of an older age 
at diagnosis. The overall 5- and 10-year survival rates of 
MBC patients are around 60% and 40%, respectively. When 
grouped by stage at presentation, overall survival rate is 
78% and 55% for stage I, 66% and 39% for stage II, and 
39% and 21% for stage III disease, at 5 and 10 years, respec-
tively [57]. Overall, survival rates differ significantly 
according to race/ethnicity. Compared to white men, black 
men have features of more aggressive disease as higher 
histologic grade, larger tumor size, and higher rate of 
nodal involvement. Worse prognosis in black men after 
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adjustment to clinical, demographic, and treatment factors 
has been shown [58].
BC mortality and survival rates have improved signifi-
cantly over time for both male and female BC, but the rela-
tive improvement was less significant for men compared 
with women [7]. Decline in FBC mortality rates are attrib-
uted to adjuvant systematic therapy and screening mammog-
raphy. Decline in MBC mortality would likely reflect just the 
impact of adjuvant systematic treatment since men do not 
receive screening mammography. However, the improve-
ment for male is smaller if compared to female BC patients, 
suggesting underutilization or non-appropriate utilization of 
adjuvant therapy.
63.7  Oncogenetic Counseling, Screening, 
and Surveillance
Genetic counseling should be offered to MBC patients 
based on their increased risk of BRCA mutations, particu-
larly in the context of a family history of breast/ovarian can-
cer. The National Comprehensive Cancer Network (NCCN) 
recommendation indicates that all MBC patients should be 
offered genetic counseling and testing based on their risk of 
carrying a deleterious mutation that might be relevant to 
their own care or the care of their family members. Risk 
assessment models to estimate the risk of carrying a BRCA 
mutation, such as BRCAPRO, have been validated for use 
in male patients [59–61].
Because the age-standardized incidence of MBC is only 
1/100,000 person-years with lifetime risk of about 1/1000, 
there is no role for breast screening in the general male 
population. On the other hand, screening for BC in men at 
higher BC risk, including those with BRCA1/2 mutations, 
strong family history of BC, such as affected mother and/or 
sister, Klinefelter’s syndrome, or transgenders [62, 63], 
should be undertaken and should be available preferably in 
a clinical trial. Extrapolating from FBC, NCCN recom-
mends that men at higher BC risk have a clinical breast 
exam every 6 to 12 months and consider having a mammo-
gram at age 40. However, as the value of breast imaging 
remains uncertain in men, mammography and ultrasound 
should be considered. Men with a BRCA1/2 gene mutation 
should also have prostate cancer screening starting at age 
40. Men at higher BC risk should also be aware of the 
warning signs of BC and should be taught for breast 
self-examination.
The risk of a new BC is higher in MBC survivors. MBC 
patients had a 30-fold increased risk of developing a con-
tralateral BC, and this risk is greatest in men who were 
younger than 50 years at BC diagnosis. Thus, male survi-
vors of early stage BC could benefit most from breast 
screening. MBC survivors are also at risk of certain non-
breast second malignancies, prostate and colon cancer 
being the most common [47]. Thus, MBC survivors should 
be offered the same screening programs for non-BC as 
men in the general population, unless they are found to 
carry deleterious genetic mutations for which specific fol-
low-up is recommended. Overall, there is a clear need for 
protocols for both screening and surveillance and, more in 
general, for information and support to men diagnosed 
with BC.
63.8  Treatment Options
To date, because there have been few evidences supporting 
a specific therapeutic approach in MBC, the majority of cli-
nicians base their treatment recommendations on their per-
sonal experience with this disease and on the data of 
FBC. Indeed, the small numbers of MBC seen in any unit 
annually have precluded significant trials being carried out, 
and treatment of MBC often mirrors that of FBC despite 
some not negligible differences. Overall, with some minor 
variations, MBC treatment follows the same indications as 
female postmenopausal BC, with surgery, radiotherapy, and 
systemic therapy.
63.8.1  Treatment of Early-Stage Disease
63.8.1.1  Surgical Management
The goals of BC surgery include complete resection of the 
primary tumor with negative margins to reduce the risk of 
local recurrences and pathologic staging of the tumor and 
axillary lymph nodes to provide prognostic and/or predictive 
information.
In early-stage MBC patients, primary standard treat-
ment is a modified radical mastectomy with axillary dis-
section [64]. This is primarily due to a paucity of breast 
tissue in men as well as the fact that in male breast, the 
tumor usually affects central quadrant. Locoregional dis-
ease control to this treatment is generally similar to those 
seen in women with BC. Conservative breast surgery has 
produced encouraging results for the treatment of early-
stage MBC patients, although in males a larger tumor size 
and a higher rate of chest wall infiltration are found com-
pared to female patients. Overall, breast conservation has 
also been used, and results have been similar to those seen 
in women with BC [65].
Surgical assessment of the axillary lymph nodes is an 
essential part of primary BC therapy; although men with 
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early-stage disease typically undergo axillary lymph node 
dissection, the use of sentinel lymph node biopsies is increas-
ing [66, 67]. If the sentinel lymph node contains cancer, a 
full axillary lymph node dissection may be needed, depend-
ing on the size of the cancer in the lymph node as well as 
what other treatment is planned. In a recent SEER analysis, 
19% of men were treated with lumpectomy [68]. Obviously, 
if breast-conserving surgery is done, it is usually followed 
by radiation therapy. External beam radiation is the usual 
type of radiation therapy for men with BC. This usually 
includes the chest wall where the breast was removed and, 
depending on the size and extent of the cancer, may include 
the underarm area, supraclavicular lymph nodes, and inter-
nal mammary lymph nodes.
Rates of contralateral preventive mastectomy in men 
who received a diagnosis of unilateral invasive BC nearly 
doubled between 2004 and 2011. In fact, in 2004, about 
3% of men had contralateral preventive mastectomy 
while, in 2011, men who had contralateral preventive 
mastectomy were 5.6%, with a relative increase of 86.7% 
[69]. However, this increase has occurred despite the 
lack of evidence for a survival benefit from bilateral 
surgery.
Although breast reconstruction is an integral part of BC 
treatment plan and methods of reconstruction after mastec-
tomy in women are well described, to date, postmastectomy 
deformity of the male chest has not received sufficient clinical 
interest. However, body image has emerged as an area of con-
cern for MBC patients, thus deserving gender-specific atten-
tion [70].
63.8.1.2  Adjuvant Therapy
Currently, due to the rare occurrence of this disease, no con-
trolled studies have compared adjuvant treatment options in 
MBC. In this setting, responses are generally similar but not 
identical to those seen in women with BC, and hormonal 
therapy has been recommended in all receptor-positive 
patients. In men with ER+, node-negative BC, endocrine 
therapy with tamoxifen is usually recommended [71]. In men 
with node-positive tumors, both chemotherapy and tamoxi-
fen have been used and can increase survival to the same 
extent as in women with BC. However, there are limited data 
regarding adjuvant chemotherapy use; to date most clinicians 
offer either an anthracycline or anthracycline- taxane- based 
schedules to men who are classified at a high risk of recur-
rence based on the presence of axillary lymph nodal disease, 
larger tumors, younger age, and ER-negative tumors [72].
While the data supporting adjuvant chemotherapy in 
women are strong, there is little information on the effective-
ness of adjuvant chemotherapy in men. However, most clini-
cians use similar guidelines for adjuvant chemotherapy in 
male and female patients. To date only one study has been 
performed to determine which male patients would derive 
benefit from adjuvant treatment as measured by the standard-
ized 21-gene RT-PCR assay [73]. A similar gene expression 
profile has been found in male compared with female BCs. If 
these preliminary data will be confirmed by prospective 
studies, this testing may also be a reasonable help to guide 
the treatment of early stage, ER+, lymph node-negative 
MBC (Table 63.3) [74].
63.8.2  Treatment of Metastatic Disease
Advanced-stage disease at BC diagnosis is more frequently 
observed in men than in women; although a very small 
selected subset of patients with metastatic BC should be 
approached with curative intent, it is a generally held belief 
that once the patient with BC develops clinically detectable 
metastases beyond the regional lymph nodes, the disease is 
incurable [64]. The goals of care are to optimize both length 
and quality of life.
To date, clinical management of metastatic BC is similar 
in male and female patients. Treatment choice should take 
into account at least these factors: tumor burden, metastatic 
de novo or recurrence, hormonal receptors and HER2 status, 
previous therapies and/or toxicities, and disease-free inter-
val. Given that the vast majority of men have ER+ tumors, 
hormonal therapy is the upfront approach. Tamoxifen has an 
established efficacy and toxicity profile in metastatic male 
BC, with an approximate 50% response rate, and is consid-
ered the standard first-line approach.
For male patients with hormone-refractory disease or rap-
idly progressing visceral metastases, chemotherapy can pro-
vide significant palliation. The type of chemotherapy is 
similar to the one used in the adjuvant setting, with anthracy-
cline and taxanes as the backbone of the chemotherapy regi-
mens. In particular, in the absence of medical contraindications, 
anthracycline- or taxane-based regimens, preferably as a 
single agent, would usually be considered as first-line che-
motherapy for HER2-negative MBC, in those patients who 
have not received these regimens as adjuvant treatment and 
for whom chemotherapy is appropriate (Table 63.3). Similarly 
to female, in MBC patients pretreated with an anthracycline 
and a taxane and who do not need combination chemother-
apy, single-agent capecitabine, vinorelbine, and eribulin are 
the preferred choices. The effectiveness of anti-HER2 agents 
in her2-neu overexpressing male breast cancer is unproven, 
but certainly it seems reasonable given the strong evidence in 
support of trastuzumab in women with breast cancer. Finally, 
no gender-specific trial have been designed so far testing 
mTor or CDK4/6 inhibitors.
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